Pictured: Peter Keeling, CEO Diaceutics
Peter Keeling is CEO of Diaceutics, a leading data analytics and implementation service provider in diagnostic commercialization. The company reported a rise in revenue and profit in 2019, and has said its global database on pharmaceutical labs and patients can help identify at-risk groups from Covid-19
Diaceutics, a leading data analytics and implementation service provider in diagnostic commercialization, reported a rise in revenue and profit in 2019 of 30 percent, an impressive £13.4 million (€12.06m), up from £10.4 million the previous year.
They also listed 10 new clients to its customer list, and to date they work with 36 pharmaceutical firms across the world, all of which are currently working around the clock to help aid in the treatment and prevention of Covid-19.
Diaceutics has said its global database on pharmaceutical labs and patients can help identify at-risk groups from Covid-19, and help tests for prescriptions of future approved treatments be pushed through quickly.
Using data, Keeling’s company has ensured pharmaceutical businesses make accurate diagnostic tests, and testing programmes, on all new products.
Speaking on this development, CEO Peter Keeling said: “As drug companies turn to us and say, ‘we’re going to launch this drug, so how do we make sure we get testing to the right sites?’ we want the answers ready.
“This virus is spreading with unprecedented speed. Diagnostic testing and labs are rising to the challenge as fast as they can. I’m not sure there’s anything we could have done faster, yet this crisis does illustrate, for the everyday person, that there is a shortage of testing.”
Keeling has been the CEO of Diaceutics since its foundation in 2005. Since that time, the pharmaceutical industry has increased investment in precision medicine which tailors treatments to specific patients. Diaceutics has been at the helm of this development.
Using data, Keeling’s company has ensured pharmaceutical businesses make accurate diagnostic tests, and testing programmes, on all new products. This has also aided in determining individual treatment plans.
The company is quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, and is enabling Pharma to accelerate market penetration and achieve a better return on precision medicine therapies by helping revolutionise patient testing.
Diaceutics has established offices in Belfast, Dundalk, New Jersey, and Singapore. This has helped the company gain a foothold in international markets and has solidified its status as a global enterprise. It has 2,500 labs and 227 million patients in its database.
Business & Finance, Business Person of the Month
Business & Finance, in association with KPMG, rewards excellence in business through the ‘Business Person of the Month’ award. This award seeks to recognise noteworthy achievements in business leadership, and, particularly, those that make a telling contribution to the wider business community in Ireland.